EPA
DRAFT, April 29, 2005
At
a glance:
|
CAPABILITIES
|
INFORMATION
|
|
Functions:
|
Targets:
|
Applications:
|
Information
Sources:
|
Information
Provided:
|
|
|
Detection
|
ü
|
Biological
Agents
|
ü
|
Water
Security
|
ü
|
No
Vendor Response;
|
ü
|
General
Product Information
|
|
ü
|
Decontamination
|
|
Chemical
Agents
|
|
Bldg.
Structures
|
General
Info Only
|
ü
|
Performance
Information
|
|
|
Remediation
|
|
Toxic
Ind. Chemicals
|
|
Bldg.
Materials
|
|
Vendor
Supplied Info
|
ü
|
Cost
Information
|
|
|
|
|
Radiological
Agents
|
ü
|
Air
|
ü
|
3rd
Party Test Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Overview
of Technology:
The
Mold Removal Air Disinfection (MRAD) technology decontaminates
the air of pathogenic forms of bacteria and viruses, including
mold spores and the submicron cold, flu, and tropical fever
pathogens small enough to pass through high-efficiency
particulate air filters. The
technology is installed in a central air system’s new or
existing ductwork and operates without reducing the air flow
velocity. MRAD chambers
use steady-state ultraviolet irradiation as the sterilization
agent and maintain clinical-standard disinfected air at
heating, ventilation, and air conditioning (HVAC) flow rates.
Other vendor-produced units using the MRAD technology
include a portable field unit for air and water and a water
decontamination system for buildings.
Performance
v
The
technology can produce a kill ratio for bacteria and viruses
of up to 99.999 percent and a kill ratio for mold spores of up
to 99.9 percent.
v
The
system can be used for extended periods of time without
maintenance.
v
Independent
testing of the system has been performed by a number of third
party laboratories.
Deployment
v
The
system is typically installed in a building’s HVAC system,
but portable units can be deployed in the field.
v
The
system can be used for tactical quarantine or isolation
purposes in a SARS-like emergency.
v
The
system is currently being used in hospitals and other medical
care facilities.
Product
Description
MolecuCare,
Inc.’s, Mold Removal Air Disinfection (MRAD) technologies
decontaminate air at heating, ventilation, and air conditioning
(HVAC) flow rates. The
technologies kill pathogenic forms of bacteria and viruses,
including mold spores and the submicron cold, flu, and tropical
fever pathogens that are small enough to pass through
high-efficiency particulate air (HEPA) filters.
Unlike filtering and ionizing air cleaning, MRAD chambers
do not store microbes for manual removal and disposal.
The MRAD technologies use ultraviolet energy to
inactivate airborne microorganisms at specified air flow rates
and ultraviolet (UV) irradiation input.
The technologies use the blower power of the central air
system to decontaminate at that same rate as HVAC air moving
through the building. Also, MRAD quantum optic technology can be
used to decontaminate and disinfect potable water.
The
MRAD technologies are available in four different assemblages,
depending on user requirements:
1.
CMRAD©/HVAC – The Central MRAD (CMRAD) for
whole-building indoor air decontamination is installed in
existing or new HVAC ductwork. The
CMRAD system is bidirectional, meaning that when the blowers are
off and the air currents flow in the reverse direction, the
CMRAD disinfects in either flow direction. Reverse airflow is
caused by atmospheric pressure change when power is down.
Filters release microbes into the building air that were
captured by powered flow direction. In an emergency as would
cause power loss, CMRAD functions on batteries at full capacity
regardless of air flow direction. The chambers are configured to
accommodate a wide range of air flow rates and to provide the
desired levels of bioprotection.
The geometry of the modules can be changed to accommodate
the space constraints typical of ductwork retrofits.
The power supply needed to run the CMRAD is 1,400 to
1,800 watts, which can be provided by batteries or an assigned
generator. System maintenance includes replacing a lamp every 2
years.
2.
PAR© – The Portable Air Remedy (PAR) is a
tandem series of CMRAD units on carts or in an upright, wheeled
case with blowers. PAR may be moved about in a building to
locations of emergency and routine alterations where mold is
disturbed. PAR also can
be used for tactical quarantine or isolation purposes in a SARS-like
emergency. This
technology can be used to create a safe air space by placing it
in a mobile tent or emergency triage enclosure.
3.
PWR© – The Portable Water Remedy (PWR)
consists of a 1½-ton water recovery machine and a ½-ton
generator. PWR can be
used to treat over 4,000 cubic meters of water per hour.
This technology can be used to treat water at an
emergency site rather than trucking in water from another
location.
4.
AQUAIRE© – The AQUAIRE system
decontaminates both air and water and is intended for
residences. It is
installed on the same floor base as furnace equipment and is
added to a forced-air furnace or central air conditioning unit
for preventive, whole-building air disinfection.
Accessories:
MRAD units can be provided with additional control panels
for remote operation (see below).
Accessories for the AQUAIRE include a stainless-steel
auto flush system, auto feedback density and turbidity monitor
sensing, a chart recorder with computer input, and a touch panel
control.
Throughput
of Product:
The MRAD systems match the throughput of the existing
systems in which they are installed.
With an MRAD system installed, the amount of air moving
through an existing HVAC system will remain the same.
Portability:
The PAR emergency and mold removal renovation, Portable
Air Remedy system can be transported and operated at a temporary
location. The system’s
dimensions range from 2.41 by 1.1 by 1.2 meters to 3.9 by 1.4 by
1.4 meters. The system is
mounted on a roll-in/roll-out cart.
Depending on the model CFM, the system runs on 6.5 to
23.0 amperes at 220 volts and 9-13 amperes at 125 volts.
Operation
and Maintenance, AIR:
After an MRAD system has been professionally installed,
it is ready for operation immediately.
Each unit includes a performance monitor and control
panel located at the unit. An
optional remote panel provides a wall-mounted operation
indicator with an on/off switch.
Cleaning
and lamp replacement are required periodically for an MRAD
system. MolecuCare offers
a maintenance contract for large building installations that
covers monitor inspection, cleaning, and lamp replacement
without additional charges other than the cost of replacing any
damaged equipment. MolecuCare
also conducts performance tests for the removal of specific
microorganisms of concern and microorganisms with similar
physical characteristics. Culture
tests are conducted at MolecuCare’s expense under a service
agreement to the extent specified each year in the contract.
However, any test reports prepared by a certified and
qualified laboratory are billed to the MRAD user.
Pre-Treatment
Requirements:
The MRAD requires professional installation before use.
No pre-treatment requirements exist.
By-Products:
The MRAD technology produces no by-products.
Post-Treatment
Requirements:
The MRAD technology requires no post-treatment.
Training:
Training for installation of the MRAD technology is
available from MolecuCare.
Technical
Support:
MolecuCare products are warranty-protected for 10 years
against defects in materials and workmanship that affect
performance. The warranty
includes product replacement, repair, or upgrading, as required,
at no cost to the purchaser except for the cost of lamps,
shipping, or installation. A
discount trade-in option for lamp exchange is available under
the annual maintenance contract at an additional cost.
In-house technical support is available to customers at
no charge.
Health
and Safety:
No specific health and safety issues have been identified
for use of the MRAD technology. A
professional contractor should be used to install an MRAD
system.
Performance
Summary
The
following independent studies have been conducted for the MRAD
technology:
1.
Yale University School of Medicine Dept Molecular
Biophysics and Biochemistry, in association with Prof/Dr William
Koingsberg, Chair
2.
American Sterilizer Corporation, Bacteriology Laboratory,
Joseph P Dalmasso, Ph.D., Director, Apex N.C.
3.
American Sterilizer Corporation, Media , PA., Joseph P
Dalmasso, Ph.D. Director
4.
Loma Linda University School of Dentistry, Loma Linda,
CA, James Kettering, Ph.D., Microbiology, Prof Kenneth Wical,
DDS
5.
Barnabus Hospital AIDS Dental Prosthetics, Sterilizer Rm,
Gen’l Hospital Emergency Room, Surgery and AIDS Drug Resistant
Tuberculosis Intensive Care Isolation, FDA
Non Significant Risk Trials
6.
Nelson Laboratories, Inc., MRAD high velocity testing of
the MolecuCare steady-state chamber on July 22, 1997. Testing
conducted for MolecuCare, Inc.
7.
International Test and Balance, Inc., performed testing
and analysis for mold contamination in MRAD chambers in
residential areas on June 10, 2002.
Testing and analysis conducted for MRAD, Inc.
The
performance information in this summary report was provided by
Nelson Laboratories, Inc.,
which performed an aerosol test to evaluate the MRAD
system’s ability to inactivate microbes.
The test was run using both the low air flow and high air
flow settings, without filtering.
Various microorganisms were used for the test.
Bacillus subtilis
endospores were chosen because of their resistance to drying.
Staphylococcus
aureus and Pseudomonas
aeruginosa were chosen to represent clinically significant
microorganisms that are among the leading causes of nosocomial
infections in hospitals. The
bacteriophage fX-174
was chosen because it is one of the smallest known viruses (with
a size of 25 to 27 nanometers) and is commonly used as a
surrogate for human virus barrier studies.
Aspergillus niger
spores were selected because they are among the organisms most
resistant to UV irradiation and are common environmental
contaminants.
Technology
Performance – Effectiveness:
The results of the Nelson Laboratories, Inc., test are
summarized below. These percentages are kill of a visual fog
density microbe suspension challenge without filter for a 250
millisecond excursion through the unit at threshold (lowest)
kill power.
|
Organism
|
Low
Flow
|
High
Flow
|
|
(%
Reduction)
|
(%
Reduction)
|
|
B.
subtilis
|
95.2
|
94.3
|
|
S.
aureus
|
99.998
|
94
|
|
Ps.
aeruginosa
|
98.2
|
88
|
|
fX-174
|
99.98
|
93.3
|
|
A.
niger
|
87
|
96.9
|
Technology
Performance – Penetration, WATER:
According to the vendor, the MRAD can penetrate up to
10.8 inches of air at 68.1 ft/sec.
The water technologies can penetrate 1.2 inches of water
at 19 ft/sec.
Cost
Information
January
2005 cost information provided by the vendor is detailed below.
Throughput rates range above 30 M2/min from equipment
size approximately 1.8 X 5.5 X 1.4 meters for water disinfection,
“purification”.
|
Category
|
Cost
|
|
Product
Base Cost
|
-
Water technology: from $32,175
@ 580 gpm, truck emergency units (PWR)
w/generator available
-
Air technology: $2,200 @400 cfm to $6,125 @ 5500 cfm
Higher cfm available
-
Base costs for specific MRAD units are provided on the
vendor’s web site
|
|
|
A
list of installation contractors is available on the
vendor’s web site
|
|
|
The
annual cost for a service contract has not been provided
by the vendor and depends upon the number of units in
the building.
|
|
|
-
Water technology
-
Stainless-steel auto flush system and auto feedback
density and turbidity monitor sensing: $4,000
-
Chart recorder with computer input and touch panel:
$9,000
-
Air technology
-
Remote Panel: $300
Auto response: contact factory
|
|
Consumable
Material Cost
|
Replacement
lamps
|
|
Training
Cost
|
|
|
Warranty
Information
|
|
|
Technical
Service
|
|
References
and Additional Information
1.
International Test and Balance, Inc. 2002.
“Test and Analysis – MRAD Chamber Effect.“
Winnebego, Illinois. June.
2.
MolecuCare, Inc. 2004.
MRAD Product Booklet Provided to Eric Koglin, U.S. Environmental
Protection Agency. September
15.
3.
MolecuCare, Inc. 2005.
Web Site. Accessed
on January 14, 2005. Online
Address: www.molecucare.com.
4.
Nelson Laboratories, Inc.
1997. “Aerosol
Challenge Testing of the MolecuCare H-10 Steady-State
Chamber.” Protocol No.
9707102-04. Laboratory
No. 105759. Salt Lake
City, Utah. July.
Notice
and Disclaimer
Preparation
of this report has been funded wholly or in part by the U.S.
Environmental Protection Agency under Contract Number
68-W-02-034. Mention of
trade names or commercial products does not constitute an
endorsement or recommendation for use.
| U.S.
EPA ORD NHSRC |
DRAFT
- APRIL 2005
|
|